Aurora Cannabis has responded to Curaleaf's attempt to halt its at-the-market (ATM) program, calling Curaleaf's hostile bid undervalued and financially risky due to Curaleaf's heavy debt load. Aurora emphasizes that its ATM program, established before Curaleaf's bid, supports its long-term growth strategy and acquisitions, especially in Canada and the UK. The company's board unanimously recommends shareholders reject Curaleaf's offer by taking no action and not tendering shares, highlighting Aurora's debt-free status and strong cash position as advantages over Curaleaf's indebtedness. Aurora also filed a complaint with the Alberta Securities Commission over regulatory deficiencies in Curaleaf's bid, urging shareholders to consider the risks of accepting the offer.
Aurora Cannabis shares are trading at USD 3.83 on Pluang as of Sep 15, 2026 01:21 WIB, showing a positive 1-day change of 2.54%. The stock's market capitalization stands at $236.56 million, reflecting its current valuation in the health sector. Investors can note that the share price remains below its 52-week high of $6.23 but above the 52-week low of $2.58, indicating some recovery potential amid ongoing corporate developments.
Tilray Brands reported a first-quarter revenue record, rising 23% year-over-year, driven by gains in its beer and distribution segments following the BrewDog acquisition. However, its core cannabis sales declined, falling to $56.1 million, causing in...
Aurora Cannabis has completed a major expansion of its Leuna facility in Germany, now renamed Aurora Horizon, more than doubling its expected annual cannabis flower output. The upgraded site integrates Aurora's proven cultivation techniques and propr...
Aurora Cannabis announced that its Special Committee will conduct a thorough review of Curaleaf's revised hostile takeover bid offering US$5.00 per share. Shareholders are advised to take no action until the Board provides a formal recommendation, ex...
Aurora Cannabis responded to Curaleaf's announcement of a revised hostile takeover bid offering $5.00 per share, including cash and Curaleaf shares. Aurora's Special Committee will thoroughly review the formal revised offer before recommending action...
